Nottingham Advisors Inc. Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Nottingham Advisors Inc. lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 30.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,488 shares of the company’s stock after selling 2,000 shares during the quarter. Nottingham Advisors Inc.’s holdings in Johnson & Johnson were worth $727,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Butensky & Cohen Financial Security Inc. increased its stake in Johnson & Johnson by 3.7% during the first quarter. Butensky & Cohen Financial Security Inc. now owns 24,220 shares of the company’s stock worth $3,831,000 after purchasing an additional 864 shares during the period. Chickasaw Capital Management LLC increased its position in Johnson & Johnson by 1.8% during the first quarter. Chickasaw Capital Management LLC now owns 18,237 shares of the company’s stock worth $2,885,000 after buying an additional 314 shares during the period. Beese Fulmer Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 2.9% in the first quarter. Beese Fulmer Investment Management Inc. now owns 121,402 shares of the company’s stock valued at $19,205,000 after acquiring an additional 3,459 shares during the period. Benchmark Wealth Management LLC grew its position in shares of Johnson & Johnson by 74.2% during the first quarter. Benchmark Wealth Management LLC now owns 2,716 shares of the company’s stock worth $430,000 after acquiring an additional 1,157 shares during the last quarter. Finally, Atlas Brown Inc. raised its position in Johnson & Johnson by 7.6% in the 1st quarter. Atlas Brown Inc. now owns 34,599 shares of the company’s stock valued at $5,473,000 after purchasing an additional 2,448 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Wells Fargo & Company upped their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday. Citigroup upped their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, TD Cowen decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $175.93.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ traded down $0.17 during trading hours on Thursday, reaching $164.11. 610,770 shares of the company’s stock traded hands, compared to its average volume of 7,014,389. The firm has a market capitalization of $394.96 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 2.65 and a beta of 0.52. The business’s fifty day simple moving average is $162.81 and its two-hundred day simple moving average is $154.59. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.66 EPS. Analysts predict that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.